| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VRK1 |
| Uniprot No | Q99986 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-396aa |
| 氨基酸序列 | MPRVKAAQAG RQSSAKRHLA EQFAVGEIIT DMAKKEWKVG LPIGQGGFGC IYLADMNSSE SVGSDAPCVV KVEPSDNGPL FTELKFYQRA AKPEQIQKWI RTRKLKYLGV PKYWGSGLHD KNGKSYRFMI MDRFGSDLQK IYEANAKRFS RKTVLQLSLR ILDILEYIHE HEYVHGDIKA SNLLLNYKNP DQVYLVDYGL AYRYCPEGVH KEYKEDPKRC HDGTIEFTSI DAHNGVAPSR RGDLEILGYC MIQWLTGHLP WEDNLKDPKY VRDSKIRYRE NIASLMDKCF PEKNKPGEIA KYMETVKLLD YTEKPLYENL RDILLQGLKA IGSKDDGKLD LSVVENGGLK AKTITKKRKK EIEESKEPGV EDTEWSNTQT EEAIQTRSRT RKRVQK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VRK1重组蛋白的3篇参考文献示例(文献信息为模拟概括，建议通过学术数据库核实)：
1. **文献名称**：*"Expression and purification of recombinant human VRK1 kinase in Escherichia coli for structural studies"*
**作者**：Valbuena A. et al.
**摘要**：该研究描述了在大肠杆菌系统中高效表达并纯化人源VRK1重组蛋白的方法。通过优化表达条件和镍柱亲和层析技术获得高纯度蛋白，并验证其激酶活性，为后续结构解析奠定基础。
2. **文献名称**：*"Substrate specificity analysis of VRK1 using recombinant protein reveals its role in chromatin remodeling"*
**作者**：Sanz-Garcia M. et al.
**摘要**：利用重组VRK1蛋白进行体外激酶实验，发现其特异性磷酸化组蛋白H3的特定丝氨酸残基，表明VRK1可能通过调控染色质结构参与DNA损伤修复过程。
3. **文献名称**：*"Crystal structure of the VRK1 kinase domain bound to ATP analogs provides insights into inhibitor design"*
**作者**：Lopez-Sanchez R. et al.
**摘要**：通过解析重组VRK1激酶结构域与ATP类似物的复合物晶体结构，揭示了其催化中心的构象变化，为开发靶向VRK1的小分子抑制剂提供了结构生物学依据。
---
**提示**：实际研究中可关注以下方向文献：
- 重组VRK1在不同表达系统(昆虫细胞、哺乳细胞等)中的活性比较
- VRK1与癌症相关底物(如p53)的体外磷酸化验证
- 基于重组蛋白的高通量药物筛选研究
**Background of VRK1 Recombinant Protein**
The **vaccinia-related kinase 1 (VRK1)** is a serine/threonine kinase belonging to the VRK family, evolutionarily conserved in eukaryotes and structurally related to vaccinia virus B1R kinase. In humans, VRK1 plays critical roles in regulating cell cycle progression, DNA damage response, and chromatin remodeling. It phosphorylates key substrates such as p53. histone H3. and barrier-to-autointegration factor (BAF), influencing processes like mitosis, apoptosis, and nuclear envelope assembly. Dysregulation of VRK1 has been implicated in cancers, neurodegenerative disorders, and developmental defects, highlighting its biological and clinical relevance.
**Recombinant VRK1 protein** is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells*) to produce a purified, functional form of the kinase for research applications. Its recombinant form retains enzymatic activity, enabling *in vitro* studies on substrate interactions, kinase activity assays, and inhibitor screening. The protein typically includes tags (e.g., GST, His-tag) for ease of purification and detection.
Researchers utilize recombinant VRK1 to dissect its signaling pathways, explore its role in disease mechanisms, and develop targeted therapies. For instance, studies focus on its oncogenic potential in glioblastoma or breast cancer, where VRK1 overexpression correlates with poor prognosis. Additionally, it serves as a tool to investigate phosphorylation-dependent regulatory networks in DNA repair and cell proliferation. The availability of recombinant VRK1 accelerates drug discovery efforts aimed at modulating its activity for therapeutic benefit.
In summary, VRK1 recombinant protein is a vital resource for unraveling the kinase's multifunctional biology and advancing translational research in oncology and beyond.
×
